%0 Journal Article
%T Prognostic Assessment of HLM Score in Heart Failure Due to Ischemic Heart Disease: A Pilot Study.
%A D'Amato A
%A Severino P
%A Mancone M
%A Mariani MV
%A Prosperi S
%A Colombo L
%A Myftari V
%A Cestiè C
%A Labbro Francia A
%A Germanò R
%A Pierucci N
%A Fanisio F
%A Marek-Iannucci S
%A De Prisco A
%A Scoccia G
%A Birtolo LI
%A Manzi G
%A Lavalle C
%A Sardella G
%A Badagliacca R
%A Fedele F
%A Vizza CD
%J J Clin Med
%V 13
%N 11
%D 2024 Jun 4
%M 38893033
%F 4.964
%R 10.3390/jcm13113322
%X Background: Ischemic heart disease (IHD) represents the main cause of heart failure (HF). A prognostic stratification of HF patients with ischemic etiology, particularly those with acute coronary syndrome (ACS), may be challenging due the variability in clinical and hemodynamic status. The aim of this study is to assess the prognostic power of the HLM score in a population of patients with ischemic HF and in a subgroup who developed HF following ACS. Methods: This is an observational, prospective, single-center study, enrolling consecutive patients with a diagnosis of ischemic HF. Patients were stratified according to the four different HLM stages of severity, and the occurrence of CV death, HFH, and worsening HF events were evaluated at 6-month follow-up. A sub-analysis was performed on patients who developed HF following ACS at admission. Results: The study included 146 patients. HLM stage predicts the occurrence of CV death (p = 0.01) and CV death/HFH (p = 0.003). Cox regression analysis confirmed HLM stage as an independent predictor of CV death (OR: 3.07; 95% IC: 1.54-6.12; p = 0.001) and CV death/HFH (OR: 2.45; 95% IC: 1.43-4.21; p = 0.001) in the total population of patients with HF due to IHD. HLM stage potentially predicts the occurrence of CV death (p < 0.001) and CV death/HFH (p < 0.001) in patients with HF following ACS at admission. Conclusions: Pathophysiological-based prognostic assessment through HLM score is a potentially promising tool for the prediction of the occurrence of CV death and CV death/HFH in ischemic HF patients and in subgroups of patients with HF following ACS at admission.